Matthew Vander Heiden

Matthew Vander Heiden

Associate Professor of Biology; Associate Director, Koch Institute for Integrative Cancer Research

Matthew Vander Heiden is interested in the role that cell metabolism plays in mammalian physiology, with a focus on cancer.

617-715-4471

Phone

76-561

Office

mvh@mit.edu

Email

Peter Jansen

Assistant

617-252-1163

Assistant Phone

Education

PhD 2000, University of Chicago; MD 2002, University of Chicago

Research Summary

We study the biochemical pathways cells use and how they are regulated to meet the metabolic requirements of cells in different physiological situations. We focus on the role of metabolism in cancer, particularly how metabolic pathways support cell proliferation. We aim to translate our understanding of cancer cell metabolism into novel cancer therapies.

Awards

  • Howard Hughes Medical Institute Faculty Scholar, 2016
  • SU2C Innovative Research Grant Recipient, 2016

Recent Publications

  1. PKM2 is not required for pancreatic ductal adenocarcinoma. Hillis, AL, Lau, AN, Devoe, CX, Dayton, TL, Danai, LV, Di Vizio, D, Vander Heiden, MG. 2018. Cancer Metab 6, 17.
    doi: 10.1186/s40170-018-0188-1PMID:30386596
  2. Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate. Dexter, JP, Ward, PS, Dasgupta, T, Hosios, AM, Gunawardena, J, Vander Heiden, MG. 2018. J. Biol. Chem. , .
    doi: 10.1074/jbc.RA118.004278PMID:30381394
  3. Microenvironmental regulation of cancer cell metabolism: implications for experimental design and translational studies. Muir, A, Danai, LV, Vander Heiden, MG. 2018. Dis Model Mech 11, .
    doi: 10.1242/dmm.035758PMID:30104199
  4. Aspartate is an endogenous metabolic limitation for tumour growth. Sullivan, LB, Luengo, A, Danai, LV, Bush, LN, Diehl, FF, Hosios, AM, Lau, AN, Elmiligy, S, Malstrom, S, Lewis, CA et al.. 2018. Nat. Cell Biol. 20, 782-788.
    doi: 10.1038/s41556-018-0125-0PMID:29941931
  5. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Danai, LV, Babic, A, Rosenthal, MH, Dennstedt, EA, Muir, A, Lien, EC, Mayers, JR, Tai, K, Lau, AN, Jones-Sali, P et al.. 2018. Nature 558, 600-604.
    doi: 10.1038/s41586-018-0235-7PMID:29925948
  6. The nutrient environment affects therapy. Muir, A, Vander Heiden, MG. 2018. Science 360, 962-963.
    doi: 10.1126/science.aar5986PMID:29853672
  7. The redox requirements of proliferating mammalian cells. Hosios, AM, Vander Heiden, MG. 2018. J. Biol. Chem. 293, 7490-7498.
    doi: 10.1074/jbc.TM117.000239PMID:29339555
  8. PKM2 is not required for colon cancer initiated by APC loss. Lau, AN, Israelsen, WJ, Roper, J, Sinnamon, MJ, Georgeon, L, Dayton, TL, Hillis, AL, Yilmaz, OH, Di Vizio, D, Hung, KE et al.. 2017. Cancer Metab 5, 10.
    doi: 10.1186/s40170-017-0172-1PMID:29214019
  9. Targeting Metabolism for Cancer Therapy. Luengo, A, Gui, DY, Vander Heiden, MG. 2017. Cell Chem Biol 24, 1161-1180.
    doi: 10.1016/j.chembiol.2017.08.028PMID:28938091
  10. Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition. Muir, A, Danai, LV, Gui, DY, Waingarten, CY, Lewis, CA, Vander Heiden, MG. 2017. Elife 6, .
    doi: 10.7554/eLife.27713PMID:28826492
More Publications

Multimedia